ZEGALOGUE (AUTOINJECTOR)
Peakdasiglucagon
NDASUBCUTANEOUSSOLUTION
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZEGALOGUE (AUTOINJECTOR) (dasiglucagon) is glucagon receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGALOGUE is a subcutaneous autoinjector containing dasiglucagon, a glucagon receptor agonist approved in 2021 for treating severe hypoglycemia in patients with type 1 diabetes. It works by stimulating glucagon receptors to trigger glycogen breakdown and glucose release from the liver, providing rapid blood sugar correction without requiring reconstitution or assistance from others.
Peak8.7 years to LOE
Product is in peak commercial phase with strong market positioning; brand and commercial teams are likely at full capacity supporting growth initiatives.
Mechanism of Action
Glucagon Receptor Agonists
Pharmacologic Class:
Antihypoglycemic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
Started Sep 2024
38 enrolled
Diabetes Mellitus, Type 1
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Started May 2023
8 enrolled
HypoglycemiaType 1 Diabetes
Career Relevance
Working on ZEGALOGUE positions you in a growing specialty diabetes/hypoglycemia rescue segment with strong clinical differentiation and peak commercial momentum. The stable patent landscape and minimal generic threat through 2034 offer job security and clear promotion visibility in a focused, agile commercial team.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.